Manhattan Scientifics, Inc. (OTCMKTS: MHTX) is a development‐stage company focused on the commercialization of advanced materials and biomedical technologies. Through its core subsidiaries, the company seeks to translate proprietary research into marketable products, with an emphasis on graphene‐based solutions and next‐generation diagnostic and therapeutic devices. Manhattan Scientifics pursues strategic partnerships and licensing agreements to accelerate the transition of laboratory innovations into commercially viable offerings.
One of the company’s key business activities is the development and scale‐up of graphene nanomaterial manufacturing. Through its Australian‐based Graphene Manufacturing Group (GMG) subsidiary, Manhattan Scientifics has established pilot production lines for graphene‐enhanced conductive inks, coatings, and composite materials. These products have potential applications in flexible electronics, energy storage, and industrial sensing, leveraging graphene’s high conductivity, mechanical strength, and thermal stability.
In parallel, Manhattan Scientifics explores opportunities in the medical device and diagnostics sector. The company evaluates and acquires early‐stage technologies aimed at improving imaging contrast agents, point‐of‐care diagnostics, and minimally invasive treatment platforms. By combining its materials expertise with targeted biomedical research, Manhattan Scientifics aims to introduce solutions that address unmet needs in healthcare, particularly in fields requiring high‐resolution imaging or enhanced biocompatibility.
Headquartered in Jersey City, New Jersey, Manhattan Scientifics operates through a lean corporate structure that supports research collaborations and joint ventures across North America and Australia. The company’s leadership team comprises industry veterans and scientific advisors who guide technology development, regulatory strategy, and commercialization efforts. While still in the development phase, Manhattan Scientifics positions itself to bridge the gap between cutting‐edge laboratory discoveries and practical, scalable applications in multiple end markets.
AI Generated. May Contain Errors.
